Decoy Therapeutics raised $1.2 million to develop immunotherapies that address cancer treatment challenges by targeting immune pathways to improve efficacy while minimizing side effects.
Decoy Therapeutics raised $1.2 million to develop immunotherapies that address cancer treatment challenges by targeting immune pathways to improve efficacy while minimizing side effects.
